BR112014029807A2 - administração pulmonar de rna mensageiro - Google Patents
administração pulmonar de rna mensageiroInfo
- Publication number
- BR112014029807A2 BR112014029807A2 BR112014029807A BR112014029807A BR112014029807A2 BR 112014029807 A2 BR112014029807 A2 BR 112014029807A2 BR 112014029807 A BR112014029807 A BR 112014029807A BR 112014029807 A BR112014029807 A BR 112014029807A BR 112014029807 A2 BR112014029807 A2 BR 112014029807A2
- Authority
- BR
- Brazil
- Prior art keywords
- rnam
- pulmonary administration
- messenger rna
- pei
- lung
- Prior art date
Links
- 230000002685 pulmonary effect Effects 0.000 title abstract 2
- 108020004999 messenger RNA Proteins 0.000 title 1
- 210000004072 lung Anatomy 0.000 abstract 2
- 210000005265 lung cell Anatomy 0.000 abstract 2
- 229920002873 Polyethylenimine Polymers 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
- A61K48/0008—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'non-active' part of the composition delivered, e.g. wherein such 'non-active' part is not delivered simultaneously with the 'active' part of the composition
- A61K48/0025—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'non-active' part of the composition delivered, e.g. wherein such 'non-active' part is not delivered simultaneously with the 'active' part of the composition wherein the non-active part clearly interacts with the delivered nucleic acid
- A61K48/0041—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'non-active' part of the composition delivered, e.g. wherein such 'non-active' part is not delivered simultaneously with the 'active' part of the composition wherein the non-active part clearly interacts with the delivered nucleic acid the non-active part being polymeric
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
- A61K47/549—Sugars, nucleosides, nucleotides or nucleic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7088—Compounds having three or more nucleosides or nucleotides
- A61K31/7105—Natural ribonucleic acids, i.e. containing only riboses attached to adenine, guanine, cytosine or uracil and having 3'-5' phosphodiester links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
- A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
- A61K48/0075—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the delivery route, e.g. oral, subcutaneous
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/111—General methods applicable to biologically active non-coding nucleic acids
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Engineering & Computer Science (AREA)
- Molecular Biology (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Genetics & Genomics (AREA)
- Biotechnology (AREA)
- Biochemistry (AREA)
- Virology (AREA)
- Biomedical Technology (AREA)
- Pulmonology (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- General Engineering & Computer Science (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Microbiology (AREA)
- Plant Pathology (AREA)
- Biophysics (AREA)
- Physics & Mathematics (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicinal Preparation (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201261657344P | 2012-06-08 | 2012-06-08 | |
| PCT/EP2013/061811 WO2013182683A1 (en) | 2012-06-08 | 2013-06-07 | Pulmonary delivery of messenger rna |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| BR112014029807A2 true BR112014029807A2 (pt) | 2017-06-27 |
Family
ID=48782278
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BR112014029807A BR112014029807A2 (pt) | 2012-06-08 | 2013-06-07 | administração pulmonar de rna mensageiro |
Country Status (14)
| Country | Link |
|---|---|
| US (1) | US20150126589A1 (enExample) |
| EP (2) | EP2858677B1 (enExample) |
| JP (1) | JP6208750B2 (enExample) |
| KR (2) | KR102087643B1 (enExample) |
| CN (1) | CN104349794B (enExample) |
| AU (1) | AU2013273504B2 (enExample) |
| BR (1) | BR112014029807A2 (enExample) |
| CA (1) | CA2873274C (enExample) |
| DK (1) | DK2858677T3 (enExample) |
| EA (1) | EA037448B1 (enExample) |
| ES (1) | ES2826203T3 (enExample) |
| IN (1) | IN2014DN09744A (enExample) |
| WO (1) | WO2013182683A1 (enExample) |
| ZA (1) | ZA201408184B (enExample) |
Families Citing this family (87)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2782676C (en) | 2009-12-01 | 2021-06-15 | Shire Human Genetic Therapies, Inc. | Pharmaceutical compositions for intracellular delivery of nucleic acids and proteins and uses thereof for treatment of ureca cycle metabolic disorders |
| EP2338520A1 (de) | 2009-12-21 | 2011-06-29 | Ludwig Maximilians Universität | Konjugat mit Zielfindungsligand und dessen Verwendung |
| US8822663B2 (en) | 2010-08-06 | 2014-09-02 | Moderna Therapeutics, Inc. | Engineered nucleic acids and methods of use thereof |
| RS63430B1 (sr) | 2010-10-01 | 2022-08-31 | Modernatx Inc | Ribonukleinske kiseline koje sadrže n1-metil-pseudouracile i njihove primene |
| WO2012116715A1 (en) * | 2011-03-02 | 2012-09-07 | Curevac Gmbh | Vaccination in newborns and infants |
| WO2012116714A1 (en) | 2011-03-02 | 2012-09-07 | Curevac Gmbh | Vaccination in elderly patients |
| EP3138577A1 (en) * | 2011-03-02 | 2017-03-08 | CureVac AG | Vaccination in elderly patients |
| EP2691101A2 (en) | 2011-03-31 | 2014-02-05 | Moderna Therapeutics, Inc. | Delivery and formulation of engineered nucleic acids |
| CA3107288A1 (en) | 2011-06-08 | 2012-12-13 | Translate Bio, Inc. | Lipid nanoparticle compositions and methods for mrna delivery |
| US9464124B2 (en) | 2011-09-12 | 2016-10-11 | Moderna Therapeutics, Inc. | Engineered nucleic acids and methods of use thereof |
| DK3682905T3 (da) | 2011-10-03 | 2022-02-28 | Modernatx Inc | Modificerede nukleosider, nukleotider og nukleinsyrer og anvendelser deraf |
| DE12858350T1 (de) | 2011-12-16 | 2021-10-07 | Modernatx, Inc. | Modifizierte mrna zusammensetzungen |
| HK1206601A1 (en) | 2012-04-02 | 2016-01-15 | Moderna Therapeutics, Inc. | Modified polynucleotides for the production of biologics and proteins associated with human disease |
| US9878056B2 (en) | 2012-04-02 | 2018-01-30 | Modernatx, Inc. | Modified polynucleotides for the production of cosmetic proteins and peptides |
| US9283287B2 (en) | 2012-04-02 | 2016-03-15 | Moderna Therapeutics, Inc. | Modified polynucleotides for the production of nuclear proteins |
| US9572897B2 (en) | 2012-04-02 | 2017-02-21 | Modernatx, Inc. | Modified polynucleotides for the production of cytoplasmic and cytoskeletal proteins |
| EP2859102A4 (en) | 2012-06-08 | 2016-05-11 | Shire Human Genetic Therapies | NUCLEASE RESISTANT POLYNUCLEOTIDES AND USES THEREOF |
| HRP20220607T1 (hr) | 2012-11-26 | 2022-06-24 | Modernatx, Inc. | Terminalno modificirana rna |
| MX365409B (es) | 2013-03-14 | 2019-05-31 | Shire Human Genetic Therapies | Composiciones de ácido ribonucleico mensajero del regulador transmembrana de fibrosis quística y métodos y usos relacionados. |
| US8980864B2 (en) | 2013-03-15 | 2015-03-17 | Moderna Therapeutics, Inc. | Compositions and methods of altering cholesterol levels |
| WO2015048744A2 (en) | 2013-09-30 | 2015-04-02 | Moderna Therapeutics, Inc. | Polynucleotides encoding immune modulating polypeptides |
| WO2015051214A1 (en) | 2013-10-03 | 2015-04-09 | Moderna Therapeutics, Inc. | Polynucleotides encoding low density lipoprotein receptor |
| MX2016005239A (es) | 2013-10-22 | 2016-08-12 | Shire Human Genetic Therapies | Tratamiento con acido ribonucleico mensajero para la fenilcetonuria. |
| EP3060303B1 (en) | 2013-10-22 | 2018-11-14 | Translate Bio, Inc. | Mrna therapy for argininosuccinate synthetase deficiency |
| CA2939950C (en) | 2014-03-09 | 2023-08-22 | The Trustees Of The University Of Pennsylvania | Compositions useful in treatment of ornithine transcarbamylase (otc) deficiency |
| KR20250005450A (ko) | 2014-04-25 | 2025-01-09 | 샤이어 휴먼 지네틱 테라피즈 인크. | 메신저 rna 의 정제 방법 |
| WO2016090262A1 (en) * | 2014-12-05 | 2016-06-09 | Shire Human Genetic Therapies, Inc. | Messenger rna therapy for treatment of articular disease |
| WO2016130600A2 (en) | 2015-02-09 | 2016-08-18 | Duke University | Compositions and methods for epigenome editing |
| WO2016176191A1 (en) | 2015-04-27 | 2016-11-03 | The Trustees Of The University Of Pennsylvania | Dual aav vector system for crispr/cas9 mediated correction of human disease |
| ES2861001T3 (es) * | 2015-06-30 | 2021-10-05 | Ethris Gmbh | Polirribonucleótidos que codifican la familia del casete de unión a ATP y formulaciones de los mismos |
| DK3112469T3 (en) | 2015-06-30 | 2018-05-07 | Ethris Gmbh | EXPRESSIONS TO INCREASE THE TRANSLATION EFFECTIVENESS OF RNA MOLECULES |
| ES3009026T3 (en) | 2015-07-22 | 2025-03-25 | Univ Duke | High-throughput screening of regulatory element function with epigenome editing technologies |
| EA201890565A1 (ru) | 2015-08-25 | 2019-04-30 | Дьюк Юниверсити | Композиции и способы улучшения специфичности в геномной инженерии с применением рнк-направляемых эндонуклеаз |
| WO2017066497A2 (en) | 2015-10-13 | 2017-04-20 | Duke University | Genome engineering with type i crispr systems in eukaryotic cells |
| EP3718565B1 (en) | 2015-10-22 | 2022-04-27 | ModernaTX, Inc. | Respiratory virus vaccines |
| WO2017117210A1 (en) * | 2015-12-30 | 2017-07-06 | Visiongate, Inc. | System and method for automated detection and monitoring of dysplasia and administration of chemoprevention |
| US20190127713A1 (en) | 2016-04-13 | 2019-05-02 | Duke University | Crispr/cas9-based repressors for silencing gene targets in vivo and methods of use |
| WO2017201347A1 (en) | 2016-05-18 | 2017-11-23 | Modernatx, Inc. | Polynucleotides encoding cystic fibrosis transmembrane conductance regulator for the treatment of cystic fibrosis |
| EP4316588A3 (en) * | 2016-05-27 | 2024-05-15 | Transcriptx, Inc. | Treatment of primary ciliary dyskinesia with synthetic messenger rna |
| US10927383B2 (en) | 2016-06-30 | 2021-02-23 | Ethris Gmbh | Cas9 mRNAs |
| WO2018010815A1 (en) | 2016-07-15 | 2018-01-18 | Biontech Rna Pharmaceuticals Gmbh | Formulation for administration of rna |
| EP3487523B1 (en) | 2016-07-19 | 2023-09-06 | Duke University | Therapeutic applications of cpf1-based genome editing |
| EP3548005A4 (en) | 2016-11-29 | 2020-06-17 | Puretech Health LLC | Exosomes for delivery of therapeutic agents |
| MA50335A (fr) | 2016-12-08 | 2020-08-19 | Modernatx Inc | Vaccins à acide nucléique contre des virus respiratoires |
| US11104887B2 (en) | 2017-01-03 | 2021-08-31 | Ethris Gmbh | Ornithine transcarbamylase coding polyribonucleotides and formulations thereof |
| EA201991747A1 (ru) | 2017-02-27 | 2020-06-04 | Транслейт Био, Инк. | НОВАЯ КОДОН-ОПТИМИЗИРОВАННАЯ мРНК CFTR |
| JOP20190200A1 (ar) | 2017-02-28 | 2019-08-27 | Univ Pennsylvania | تركيبات نافعة في معالجة ضمور العضل النخاعي |
| WO2018160582A1 (en) | 2017-02-28 | 2018-09-07 | The Trustees Of The University Of Pennsylvania | Adeno-associated virus (aav) clade f vector and uses therefor |
| EP4656244A2 (en) | 2017-03-01 | 2025-12-03 | The Trustees of the University of Pennsylvania | Gene therapy for ocular disorders |
| US11879133B2 (en) | 2017-04-24 | 2024-01-23 | The Trustees Of The University Of Pennsylvania | Gene therapy for ocular disorders |
| US11591614B2 (en) | 2017-05-11 | 2023-02-28 | The Trustees Of The University Of Pennsylvania | Gene therapy for ceroid lipofuscinoses |
| CA3063531A1 (en) | 2017-05-16 | 2018-11-22 | Translate Bio, Inc. | Treatment of cystic fibrosis by delivery of codon-optimized mrna encoding cftr |
| US11793887B2 (en) | 2017-05-31 | 2023-10-24 | The Trustees Of The University Of Pennsylvania | Gene therapy for treating peroxisomal disorders |
| AU2018375163A1 (en) | 2017-11-30 | 2020-06-11 | The Trustees Of The University Of Pennsylvania | Gene therapy for mucopolysaccharidosis IIIB |
| JP7389744B2 (ja) | 2017-11-30 | 2023-11-30 | ザ・トラステイーズ・オブ・ザ・ユニバーシテイ・オブ・ペンシルベニア | ムコ多糖症ｉｉｉａ型のための遺伝子療法 |
| KR20210021943A (ko) | 2018-04-25 | 2021-03-02 | 에트리스 게엠베하 | 미립자 제형용 동결 방지제 |
| MX2021005969A (es) | 2018-11-21 | 2021-09-14 | Translate Bio Inc | Tratamiento de la fibrosis quística mediante el suministro de arnm que codifica cftr nebulizado. |
| US11351242B1 (en) | 2019-02-12 | 2022-06-07 | Modernatx, Inc. | HMPV/hPIV3 mRNA vaccine composition |
| CN118949075A (zh) * | 2019-02-14 | 2024-11-15 | 埃泽瑞斯公司 | 纤毛疾病的治疗 |
| US11065260B1 (en) * | 2020-04-13 | 2021-07-20 | Alan C Nelson | Method of treatment for reducing pulmonary inflammation in a patient with pathogen infection using oral prostacyclin analog drugs |
| KR20230010670A (ko) | 2020-05-12 | 2023-01-19 | 더 트러스티스 오브 더 유니버시티 오브 펜실베니아 | 이식유전자 발현의 drg-특이적 감소를 위한 조성물 |
| EP4171738A1 (en) | 2020-06-17 | 2023-05-03 | The Trustees of The University of Pennsylvania | Compositions and methods for treatment of gene therapy patients |
| CN116438311A (zh) | 2020-07-13 | 2023-07-14 | 宾夕法尼亚州大学信托人 | 可用于治疗夏科-马里-图思病的组合物 |
| KR20230066000A (ko) * | 2020-08-12 | 2023-05-12 | 액팀 테라퓨틱스, 인코퍼레이티드 | 면역자극성 박테리아-기초 백신, 치료제, 및 rna 전달 플랫폼 |
| IL301643A (en) | 2020-10-07 | 2023-05-01 | Regenxbio Inc | Gene therapy for ocular manifestations of CLN2 disease |
| CA3193833A1 (en) | 2020-10-09 | 2022-04-14 | Juliette HORDEAUX | Compositions and methods for treatment of fabry disease |
| US20240024507A1 (en) | 2020-12-01 | 2024-01-25 | The Trustees Of The University Of Pennsylvania | Novel compositions with tissue-specific targeting motifs and compositions containing same |
| MX2023006445A (es) | 2020-12-01 | 2023-08-10 | Univ Pennsylvania | Composiciones y usos de estas para el tratamiento del síndrome de angelman. |
| CA3209779A1 (en) | 2021-02-01 | 2022-08-04 | Regenxbio Inc. | Gene therapy for neuronal ceroid lipofuscinoses |
| AU2022258312A1 (en) | 2021-04-12 | 2023-10-26 | The Trustees Of The University Of Pennsylvania | Compositions useful for treating spinal and bulbar muscular atrophy (sbma) |
| AR125406A1 (es) | 2021-04-23 | 2023-07-12 | Univ Pennsylvania | Nuevas composiciones con motivos selectivos para el cerebro y composiciones que las contienen |
| US20250295807A1 (en) | 2021-11-15 | 2025-09-25 | The Trustees Of The University Of Pennsylvania | Compositions for drg-specific reduction of transgene expression |
| WO2023102517A1 (en) | 2021-12-02 | 2023-06-08 | The Trustees Of The University Of Pennsylvania | Compositions and methods for treatment of fabry disease |
| AR128239A1 (es) | 2022-01-10 | 2024-04-10 | Univ Pennsylvania | Composiciones y métodos útiles para el tratamiento de trastornos mediados por c9orf72 |
| WO2023183300A1 (en) * | 2022-03-22 | 2023-09-28 | The Children's Medical Center Corporation | Compositions and methods for prevention and treatment of genetic disease |
| CN119731321A (zh) | 2022-06-24 | 2025-03-28 | 图恩疗法股份有限公司 | 通过靶向基因阻遏减少低密度脂蛋白的组合物、系统和方法 |
| WO2024121160A1 (en) | 2022-12-05 | 2024-06-13 | Ethris Gmbh | Regulator(s) of energy homeostasis-encoding rna molecule(s) with increased translation efficiency |
| AU2023398931A1 (en) | 2022-12-17 | 2025-07-10 | The Trustees Of The University Of Pennsylvania | Recombinant aav mutant vectors with cardiac and skeletal muscle-specific targeting motifs and compositions containing same |
| WO2024130070A2 (en) | 2022-12-17 | 2024-06-20 | The Trustees Of The University Of Pennsylvania | Recombinant aav capsids with cardiac- and skeletal muscle- specific targeting motifs and uses thereof |
| WO2024258961A1 (en) | 2023-06-12 | 2024-12-19 | The Trustees Of The University Of Pennsylvania | Aav gene therapy for mucopolysaccharidosis iiib |
| TW202516019A (zh) | 2023-06-29 | 2025-04-16 | 賓州大學委員會 | 具中樞神經系統靶向模體的突變aav及含有其之組成物 |
| WO2025035143A1 (en) | 2023-08-10 | 2025-02-13 | The Trustees Of The University Of Pennsylvania | Compositions and methods for treatment of spinal muscular atrophy |
| WO2025102034A1 (en) | 2023-11-10 | 2025-05-15 | The Trustees Of The University Of Pennsylvania | Gene therapy for barth syndrome |
| WO2025106661A1 (en) | 2023-11-14 | 2025-05-22 | The Trustees Of The University Of Pennsylvania | Compositions with cardiac and skeletal musclespecific targeting motifs and uses thereof |
| WO2025129157A1 (en) | 2023-12-15 | 2025-06-19 | The Trustees Of The University Of Pennsylvania | Gene therapy for treatment of canavan disease |
| WO2025184172A1 (en) | 2024-02-27 | 2025-09-04 | Overt Bio, Inc. | Cancer reactive t cell receptors |
| WO2025184170A1 (en) | 2024-02-27 | 2025-09-04 | Overt Bio, Inc. | Methods and compositions for improving t cell function in an immunosuppressive environment |
Family Cites Families (19)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5756353A (en) * | 1991-12-17 | 1998-05-26 | The Regents Of The University Of California | Expression of cloned genes in the lung by aerosol-and liposome-based delivery |
| FR2722506B1 (fr) * | 1994-07-13 | 1996-08-14 | Rhone Poulenc Rorer Sa | Composition contenant des acides nucleiques, preparation et utilisations |
| WO1999064094A1 (en) * | 1998-06-12 | 1999-12-16 | Aradigm Corporation | Methods of delivering aerosolized polynucleotides to the respiratory tract |
| CN1354678A (zh) * | 1999-04-02 | 2002-06-19 | 研究发展基金会 | 用于气溶胶传递的聚乙烯亚胺:dna制剂 |
| US20020086842A1 (en) * | 2000-06-26 | 2002-07-04 | Christian Plank | Method for transfecting cells using a magnetic field |
| WO2002000870A2 (en) * | 2000-06-26 | 2002-01-03 | Christian Plank | Method for transfecting cells using a magnetic field |
| WO2004033620A2 (en) * | 2001-11-02 | 2004-04-22 | Insert Therapeutics, Inc. | Methods and compositions for therapeutic use of rna interference |
| EP1592412A1 (en) * | 2003-01-31 | 2005-11-09 | Novartis AG | Down-regulation of target-gene with pei/single-stranded oligoribonucleotide complexes |
| GB0313259D0 (en) * | 2003-06-09 | 2003-07-16 | Consejo Superior Investigacion | Magnetic nanoparticles |
| MXPA05013983A (es) * | 2003-06-30 | 2006-03-02 | Canji Inc | Encapsulacion polimerica de adenovirus. |
| GB0411537D0 (en) * | 2004-05-24 | 2004-06-23 | Midatech Ltd | Nanoparticles comprising rna ligands |
| GB0508110D0 (en) * | 2005-04-22 | 2005-06-01 | Univ Keele | Gene delivery |
| EP4174179B1 (en) * | 2005-08-23 | 2025-05-07 | The Trustees of the University of Pennsylvania | Rna containing modified nucleosides and methods of use thereof |
| DE102005042768A1 (de) | 2005-09-08 | 2007-03-15 | Ludwig-Maximilian-Universität | Magnetfeld-gesteuerter Wirkstofftransfer für die Aerosoltherapie |
| WO2009127230A1 (en) * | 2008-04-16 | 2009-10-22 | Curevac Gmbh | MODIFIED (m)RNA FOR SUPPRESSING OR AVOIDING AN IMMUNOSTIMULATORY RESPONSE AND IMMUNOSUPPRESSIVE COMPOSITION |
| WO2010037408A1 (en) * | 2008-09-30 | 2010-04-08 | Curevac Gmbh | Composition comprising a complexed (m)rna and a naked mrna for providing or enhancing an immunostimulatory response in a mammal and uses thereof |
| JPWO2010110314A1 (ja) * | 2009-03-27 | 2012-10-04 | 協和発酵キリン株式会社 | 核酸を含有する肺高血圧症治療剤 |
| EP2338520A1 (de) * | 2009-12-21 | 2011-06-29 | Ludwig Maximilians Universität | Konjugat mit Zielfindungsligand und dessen Verwendung |
| US20110229528A1 (en) * | 2010-03-12 | 2011-09-22 | Intezyne Technologies, Incorporated | Pegylated polyplexes for polynucleotide delivery |
-
2013
- 2013-06-07 BR BR112014029807A patent/BR112014029807A2/pt not_active Application Discontinuation
- 2013-06-07 KR KR1020197011630A patent/KR102087643B1/ko active Active
- 2013-06-07 CA CA2873274A patent/CA2873274C/en active Active
- 2013-06-07 WO PCT/EP2013/061811 patent/WO2013182683A1/en not_active Ceased
- 2013-06-07 EP EP13735212.6A patent/EP2858677B1/en active Active
- 2013-06-07 KR KR20147033746A patent/KR20150020288A/ko not_active Ceased
- 2013-06-07 DK DK13735212.6T patent/DK2858677T3/da active
- 2013-06-07 EP EP20189217.1A patent/EP3800254A1/en active Pending
- 2013-06-07 ES ES13735212T patent/ES2826203T3/es active Active
- 2013-06-07 CN CN201380027591.5A patent/CN104349794B/zh active Active
- 2013-06-07 AU AU2013273504A patent/AU2013273504B2/en not_active Ceased
- 2013-06-07 EA EA201401337A patent/EA037448B1/ru unknown
- 2013-06-07 JP JP2015515538A patent/JP6208750B2/ja active Active
- 2013-06-07 US US14/406,112 patent/US20150126589A1/en not_active Abandoned
-
2014
- 2014-11-10 ZA ZA2014/08184A patent/ZA201408184B/en unknown
- 2014-11-18 IN IN9744DEN2014 patent/IN2014DN09744A/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| KR102087643B1 (ko) | 2020-03-11 |
| EP3800254A1 (en) | 2021-04-07 |
| AU2013273504A1 (en) | 2014-11-27 |
| CN104349794A (zh) | 2015-02-11 |
| JP2015518874A (ja) | 2015-07-06 |
| CA2873274A1 (en) | 2013-12-12 |
| WO2013182683A1 (en) | 2013-12-12 |
| CN104349794B (zh) | 2019-01-04 |
| HK1209340A1 (en) | 2016-04-01 |
| KR20190045403A (ko) | 2019-05-02 |
| EP2858677A1 (en) | 2015-04-15 |
| EA201401337A1 (ru) | 2015-05-29 |
| US20150126589A1 (en) | 2015-05-07 |
| AU2013273504B2 (en) | 2017-12-07 |
| EP2858677B1 (en) | 2020-08-05 |
| DK2858677T3 (da) | 2020-08-31 |
| JP6208750B2 (ja) | 2017-10-04 |
| ZA201408184B (en) | 2015-10-28 |
| CA2873274C (en) | 2021-06-01 |
| KR20150020288A (ko) | 2015-02-25 |
| EA037448B1 (ru) | 2021-03-30 |
| ES2826203T3 (es) | 2021-05-17 |
| IN2014DN09744A (enExample) | 2015-07-31 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| BR112014029807A2 (pt) | administração pulmonar de rna mensageiro | |
| IN2015DN03862A (enExample) | ||
| WO2013005053A3 (en) | Progenitor cells of mesodermal lineage | |
| ZA201309343B (en) | Centrifugal blower system and fuel cell incorporating same | |
| PH12013501358A1 (en) | Nutritional compositions comprising human milk oligosaccharides and nucleotides and uses thereof for treating and/or preventing enteric viral infection | |
| WO2013166264A3 (en) | Methods for altering virus replication | |
| HK1212165A1 (zh) | 包含β-羥基-β-甲基丁酸鈣、蛋白質和低水平電解質的營養組合物 | |
| MY187609A (en) | Human milk oligosaccharides to ameliorate symptoms of stress | |
| SG10201804960RA (en) | Complement component irna compositions and methods of use thereof | |
| HK1210214A1 (en) | Modified adeno-associated virus vector compositions | |
| WO2014108571A3 (en) | Cancer drug and uses | |
| MX2013007706A (es) | Oligosacaridos de leche humana para modular la inflamacion. | |
| HUE049207T2 (hu) | Normál és tumorsejtek kismolekulás TRAIL-génindukciója rákellenes terápiaként | |
| DK3556350T3 (da) | Farmaceutisk præparat indeholdende et antiviralt aktivt dihydroquinazolinderivat med s-konfiguration i 4-stillingen | |
| AU334107S (en) | Connector plug | |
| BR112014016234A8 (pt) | composições nutricionais estabilizadas incluindo amido | |
| TWD166677S (zh) | 電連接器 | |
| TWD168568S (zh) | 電連接器 | |
| BR112014030570A2 (pt) | extratos de tomilho selvagem e uso destes | |
| MX2016005720A (es) | Composiciones y metodos para administracion de una enzima a las vias respiratorias de un sujeto. | |
| WO2014104989A8 (en) | Pharmaceutical compositions comprising aripiprazole | |
| AU334129S (en) | Connector plug | |
| TWD166678S (zh) | 電連接器 | |
| WO2010118200A3 (en) | Liposomal formulations of tocopheryl amides | |
| BR112014019486A8 (pt) | Uso de um oligossacarídeo não digerível como um suplemento materno |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| B15K | Others concerning applications: alteration of classification |
Ipc: A61K 47/00 (2006.01), C12N 15/11 (2006.01), C12N 1 |
|
| B06F | Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette] | ||
| B07D | Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette] |
Free format text: DE ACORDO COM O ARTIGO 229-C DA LEI NO 10196/2001, QUE MODIFICOU A LEI NO 9279/96, A CONCESSAO DA PATENTE ESTA CONDICIONADA A ANUENCIA PREVIA DA ANVISA. CONSIDERANDO A APROVACAO DOS TERMOS DO PARECER NO 337/PGF/EA/2010, BEM COMO A PORTARIA INTERMINISTERIAL NO 1065 DE 24/05/2012, ENCAMINHA-SE O PRESENTE PEDIDO PARA AS PROVIDENCIAS CABIVEIS. |
|
| B07E | Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette] | ||
| B06U | Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette] | ||
| B07A | Application suspended after technical examination (opinion) [chapter 7.1 patent gazette] | ||
| B09B | Patent application refused [chapter 9.2 patent gazette] | ||
| B12B | Appeal against refusal [chapter 12.2 patent gazette] |